Ocular Therapeutix Inc
$ 8.74
2.82%
06 Aug - close price
- Market Cap 2,018,270,000 USD
- Current Price $ 8.74
- High / Low $ 8.79 / 8.40
- Stock P/E N/A
- Book Value 2.66
- EPS -1.47
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.35 %
- ROE -0.73 %
- 52 Week High 16.44
- 52 Week Low 6.23
About
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company is headquartered in Bedford, Massachusetts.
Analyst Target Price
$27.09
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-03 | 2026-05-05 | 2026-02-05 | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-03-03 | 2024-11-14 | 2024-08-07 | 2024-05-07 | 2024-03-11 | 2023-11-07 |
| Reported EPS | -0.35 | -0.4 | -0.29 | -0.38 | -0.39 | -0.37 | -0.29 | -0.22 | -0.26 | -0.24 | -0.35 | -0.19 |
| Estimated EPS | -0.4 | -0.31 | -0.34 | -0.35 | -0.35 | -0.28 | -0.22 | -0.21 | -0.21 | -0.18 | -0.3 | -0.25 |
| Surprise | 0.05 | -0.09 | 0.05 | -0.03 | -0.04 | -0.09 | -0.07 | -0.01 | -0.05 | -0.06 | -0.05 | 0.06 |
| Surprise Percentage | 12.5% | -29.0323% | 14.7059% | -8.5714% | -11.4286% | -32.1429% | -31.8182% | -4.7619% | -23.8095% | -33.3333% | -16.6667% | 24% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OCUL
2026-08-08 06:41:52
Ocular Therapeutix, Inc. announced inducement equity awards granted to eight new non-executive employees. These awards, consisting of stock options and restricted stock units, were issued under the company's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) to attract and retain talent. The grants are part of the company's efforts to further its integrated biopharmaceutical goals, particularly with its investigational product candidates for retinal diseases.
2026-08-08 06:40:55
Ocular Therapeutix (NASDAQ:OCUL) has been upgraded from a "sell" to a "hold" rating by Wall Street Zen. The company reported quarterly revenue of $13.47 million and an adjusted loss of $0.35 per share, exceeding analyst estimates. Despite the upgrade, other analysts maintain a "Moderate Buy" consensus with an average price target of $25.75 for the stock.
2026-08-07 19:40:55
Ocular Therapeutix (NASDAQ: OCUL) has granted inducement equity awards to eight new non-executive employees, including stock options for up to 53,975 shares and restricted stock units for 17,450 shares, effective August 3, 2026. The stock options have an exercise price of $8.40 per share, matching the closing price on the grant date, and vest over four years, while RSUs vest in three equal annual installments, both contingent on continued service. These grants were made under the company's 2019 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
2026-08-06 19:40:38
Ocular Therapeutix Inc. (NASDAQ:OCUL) recently reported strong second-quarter results, with revenues beating expectations. Analysts have modestly increased their optimism regarding loss per share predictions for 2026, though revenue forecasts remain unchanged. The consensus price target for OCUL stock held steady at US$27.09, despite the improved loss estimates, and the company's revenue growth is expected to slow compared to both its historical performance and the wider industry.
2026-08-06 11:12:32
Ocular Therapeutix (NASDAQ:OCUL) recently released strong second-quarter results, beating revenue expectations and posting smaller-than-anticipated statutory losses. Analysts have slightly increased their optimism regarding per-share losses for 2026, though revenue forecasts remain unchanged. Despite this, the consensus price target of US$27.09 has not shifted, and the company's projected revenue growth is expected to be slower than the broader industry.
2026-08-06 11:12:08
Ocular Therapeutix, Inc. (NASDAQ:OCUL) recently reported strong second-quarter results, with revenues exceeding expectations. Analysts have maintained their revenue forecasts for 2026 at US$52.6m, while modestly increasing their optimism regarding loss per share, now predicted to be US$1.48. Despite these adjustments, the consensus price target remains unchanged at US$27.09, reflecting that the reduced loss estimates have not significantly altered the long-term valuation outlook.
